Literature DB >> 1991825

Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3.

C H Dai1, S B Krantz, R T Means, S T Horn, H S Gilbert.   

Abstract

Because polycythemia vera (PV) is a clonal hematopoietic stem cell disease with a trilineage hyperplasia, and interleukin-3 (IL-3) stimulates trilineage hematopoiesis, we have studied the response of highly purified PV blood burst-forming units-erythroid (BFU-E) to recombinant human IL-3 (rIL-3). Whereas the growth of normal blood BFU-E in vitro rapidly declined by 40 and 60% after 24 and 48 h of incubation without 50 U/ml of rIL-3, the growth of PV BFU-E declined by only 10 and 30% under the same conditions, demonstrating a reduced dependence on rIL-3. A reduced dependence of PV BFU-E on recombinant human erythropoietin (rEP) was also present. Dose-response experiments showed a 117-fold increase in PV BFU-E sensitivity to rIL-3, and a 6.5-fold increase in sensitivity to rEP, compared to normal BFU-E, whereas blood BFU-E from patients with secondary polycythemia responded like normal BFU-E. Endogenous erythroid colony (EEC) formation, which is independent of the addition of rEP, was reduced by 50% after erythroid colony-forming cells were generated from PV BFU-E in vitro without rIL-3 for 3 d, whereas rEP-stimulated erythroid colonies were unaffected. These studies demonstrate a striking hypersensitivity of PV blood BFU-E to rIL-3, which may be the major factor in the pathogenesis of increased erythropoiesis without increased EP concentrations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1991825      PMCID: PMC295089          DOI: 10.1172/JCI115009

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Diagnosis and classification of the polycythemias.

Authors:  N I Berlin
Journal:  Semin Hematol       Date:  1975-10       Impact factor: 3.851

2.  Letter: Bone-marrow responses in polycythemia vera.

Authors:  J F Prchal; A A Axelrad
Journal:  N Engl J Med       Date:  1974-06-13       Impact factor: 91.245

3.  Purification of human blood burst-forming units-erythroid and demonstration of the evolution of erythropoietin receptors.

Authors:  K Sawada; S B Krantz; C H Dai; S T Koury; S T Horn; A D Glick; C I Civin
Journal:  J Cell Physiol       Date:  1990-02       Impact factor: 6.384

4.  Polycythemia vera: stem-cell and probable clonal origin of the disease.

Authors:  J W Adamson; P J Fialkow; S Murphy; J F Prchal; L Steinmann
Journal:  N Engl J Med       Date:  1976-10-21       Impact factor: 91.245

5.  Polycythemia vera. The in vitro response of normal and abnormal stem cell lines to erythropoietin.

Authors:  J F Prchal; J W Adamson; S Murphy; L Steinmann; P J Fialkow
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

6.  Polycythemia vera: hormonal modulation of erythropoiesis in vitro.

Authors:  D W Golde; N Bersch; M J Cline
Journal:  Blood       Date:  1977-03       Impact factor: 22.113

7.  Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera.

Authors:  C J Eaves; A C Eaves
Journal:  Blood       Date:  1978-12       Impact factor: 22.113

8.  Detection of cytotoxic antibody to erythroblasts.

Authors:  S D Zaentz; J A Luna; A S Baker; S B Krantz
Journal:  J Lab Clin Med       Date:  1977-04

9.  Characterization of an erythroid precursor cell of high proliferative capacity in normal human peripheral blood.

Authors:  B J Clarke; D Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1977-03       Impact factor: 11.205

10.  Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin.

Authors:  E D Zanjani; J D Lutton; R Hoffman; L R Wasserman
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

View more
  7 in total

Review 1.  The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.

Authors:  Martha Wadleigh; D Gary Gilliland
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

2.  Complex oncogene dependence in microRNA-125a-induced myeloproliferative neoplasms.

Authors:  Shangqin Guo; Haitao Bai; Cynthia M Megyola; Stephanie Halene; Diane S Krause; David T Scadden; Jun Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-24       Impact factor: 11.205

3.  CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy.

Authors:  Kathleen M Sakamoto; David A Frank
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

4.  Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice.

Authors:  R J D'Andrea; D Harrison-Findik; C M Butcher; J Finnie; P Blumbergs; P Bartley; M McCormack; K Jones; R Rowland; T J Gonda; M A Vadas
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

Review 5.  Diagnostic and prognostic value of colony formation of hematopoietic progenitor cells in myeloid malignancies.

Authors:  Leopold Ohler; Klaus Geissler; Wolfgang Hinterberger
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

Review 6.  Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.

Authors:  Raoul Tibes; James M Bogenberger; Kasey L Benson; Ruben A Mesa
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

7.  Serum Inflammatory Factor Profiles in the Pathogenesis of High-Altitude Polycythemia and Mechanisms of Acclimation to High Altitudes.

Authors:  Hai Yi; Qianjin Yu; Dongfeng Zeng; Zhaohua Shen; Jiali Li; Lidan Zhu; Xi Zhang; Quanhong Xu; Hu Song; Peiyan Kong
Journal:  Mediators Inflamm       Date:  2021-08-25       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.